

CentraSight® Fact Sheet

Updated June 2017

- CentraSight is a first-of-kind treatment program using a tiny telescope that is implanted inside the eye to treat end-stage age-related macular degeneration (AMD), the most advanced form of AMD and the leading cause of blindness in older Americans.
- Patients with end-stage AMD have a central blind spot or missing area in their vision. This vision loss is uncorrectable by glasses, drugs or cataract surgery. Patients with end-stage AMD find it difficult or impossible to see faces, read, and perform everyday activities such as watching TV, preparing meals, and self-care. The integral component of the CentraSight treatment program is the first-ever, FDA-approved telescope implant for end-stage AMD.
- Smaller than a pea, the telescope implant uses micro-optical technology to magnify objects that would normally be seen in one's 'straight ahead' vision. This image is projected on to the healthy retina in the back of the eye not affected by the disease.
- The telescope implant has been demonstrated in clinical trials to improve quality of life by improving patients' vision so they can see the things that are important to them, increase their independence, and re-engage in everyday activities. It also may help patients in social settings, as it may allow them to recognize faces and see the facial expressions of family and friends.
- The CentraSight treatment program is generally coordinated by retina specialists who treat macular degeneration and other back-of-the-eye disorders. The treatment program focuses on comprehensive patient care, requiring prospective patients to undergo medical and vision evaluation to determine whether the patient may be a good candidate. A unique aspect of the evaluation is the ability to simulate, prior to surgery, what a person may expect to see once the telescope is implanted to determine if the improvement possible will meet the patient's expectations. After the telescope has been implanted by an eye surgeon in an outpatient procedure, the patient will need to work with vision specialists to learn how to use their new vision in their everyday activities.
- Until now, CentraSight was only available to patients 65 and over who have not had cataract surgery, a common procedure for seniors experiencing some vision loss. Now a new clinical trial launched in 2017 will evaluate the safety and effectiveness of the device for patients with end-stage AMD, who have already had a cataract removed from the eye that will be implanted. If the trial is successful, it could potentially expand the eligibility for the procedure to many more with end-stage age-related macular degeneration.
- Leading eye care centers across the country participate in the CentraSight program. To date, there are approximately 150 CentraSight provider teams, and the device has been implanted in more than 600 patients. For more information on the telescope implant and to see if you qualify for the CentraSight treatment program, visit www.CentraSight.com or call 1-877- 99SIGHT.